Literature DB >> 10195815

Effects of dexmedetomidine on rat locus coeruleus and ethanol withdrawal symptoms during intermittent ethanol exposure.

P Riihioja1, P Jaatinen, A Haapalinna, K Kiianmaa, A Hervonen.   

Abstract

In the present study, the neuroprotective effects of dexmedetomidine on rat locus coeruleus were studied during a 5-week intermittent ethanol exposure. Male Wistar rats (3 to 4 months old) were given ethanol or isocaloric sucrose by intragastric intubations three times a day for 4 days, which was followed by a 3-day withdrawal period. This 7-day cycle of ethanol exposure and withdrawal was repeated five times. Dexmedetomidine (at a dose decreasing from 30 microg/kg to 10 microg/kg, s.c.) was given to the treatment group during the withdrawal phase. The results showed that, during the 5-week experiment, dexmedetomidine significantly relieved the ethanol withdrawal syndrome, measured as the sum of the three most specific symptoms (rigidity, tremor, and irritability). The total neuron number of locus coeruleus (LC) decreased in the ethanol-treated group by 24%, compared with the nontreated control group and by 11%, compared with the sucrose-treated control group. Interestingly, the LC neuron numbers were found to decrease in the sucrose-intubated rats as well, compared with the nontreated control group. Dexmedetomidine was found to relieve ethanol-induced neuronal loss in the LC. Dexmedetomidine might be a new interesting alternative in the treatment of ethanol withdrawal syndrome, particularly due to its possible neuroprotective effects in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10195815

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  8 in total

1.  Current approaches to the recognition and treatment of alcohol withdrawal and delirium tremens: "old wine in new bottles" or "new wine in old bottles".

Authors:  Theodore A Stern; Anne F Gross; Thomas W Stern; Shamim H Nejad; Jose R Maldonado
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

2.  CRF1 Receptor-Dependent Increases in Irritability-Like Behavior During Abstinence from Chronic Intermittent Ethanol Vapor Exposure.

Authors:  Adam Kimbrough; Giordano de Guglielmo; Jenni Kononoff; Marsida Kallupi; Eric P Zorrilla; Olivier George
Journal:  Alcohol Clin Exp Res       Date:  2017-09-22       Impact factor: 3.455

Review 3.  Dexmedetomidine: applications for the pediatric patient with congenital heart disease.

Authors:  Joseph D Tobias; Punkaj Gupta; Aymen Naguib; Andrew R Yates
Journal:  Pediatr Cardiol       Date:  2011-09-10       Impact factor: 1.655

4.  Dexmedetomidine controls agitation and facilitates reliable, serial neurological examinations in a non-intubated patient with traumatic brain injury.

Authors:  Julin F Tang; Po-Liang Chen; Eric J Tang; Todd A May; Shirley I Stiver
Journal:  Neurocrit Care       Date:  2011-08       Impact factor: 3.210

Review 5.  Dexmedetomidine: a review of applications for cardiac surgery during perioperative period.

Authors:  Xiaoyu Zhang; Xuan Zhao; Yingwei Wang
Journal:  J Anesth       Date:  2014-06-10       Impact factor: 2.078

6.  Use of dexmedetomidine for the treatment of alcohol withdrawal syndrome in critically ill patients: a retrospective case series.

Authors:  Jonas P DeMuro; David G Botros; Ela Wirkowski; Adel F Hanna
Journal:  J Anesth       Date:  2012-05-15       Impact factor: 2.078

Review 7.  Dexmedetomidine for the treatment of alcohol withdrawal syndrome: rationale and current status of research.

Authors:  Andrew J Muzyk; Suzanne Kerns; Scott Brudney; Jane P Gagliardi
Journal:  CNS Drugs       Date:  2013-11       Impact factor: 5.749

8.  Dexmedetomidine as adjunct treatment for severe alcohol withdrawal in the ICU.

Authors:  Samuel G Rayner; Craig R Weinert; Helen Peng; Stacy Jepsen; Alain F Broccard
Journal:  Ann Intensive Care       Date:  2012-05-23       Impact factor: 6.925

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.